Stokes Family Office LLC grew its position in shares of Inogen, Inc. (NASDAQ:INGN - Free Report) by 29.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 163,500 shares of the medical technology company's stock after purchasing an additional 36,715 shares during the quarter. Stokes Family Office LLC owned approximately 0.69% of Inogen worth $1,499,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in the company. Royce & Associates LP boosted its position in Inogen by 167.4% during the third quarter. Royce & Associates LP now owns 51,891 shares of the medical technology company's stock worth $503,000 after purchasing an additional 32,482 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Inogen by 312.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company's stock valued at $1,694,000 after buying an additional 132,287 shares in the last quarter. BNP Paribas Financial Markets grew its stake in Inogen by 13.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 42,137 shares of the medical technology company's stock valued at $409,000 after acquiring an additional 5,131 shares during the period. Verition Fund Management LLC purchased a new stake in Inogen in the 3rd quarter worth $106,000. Finally, Paloma Partners Management Co acquired a new position in Inogen during the third quarter worth $126,000. 89.94% of the stock is currently owned by institutional investors and hedge funds.
Inogen Stock Down 1.3 %
Shares of Inogen stock traded down $0.10 during trading hours on Friday, reaching $7.35. 321,579 shares of the company's stock were exchanged, compared to its average volume of 233,771. The business has a fifty day moving average of $9.75 and a two-hundred day moving average of $9.68. The company has a market capitalization of $195.00 million, a P/E ratio of -3.27 and a beta of 1.15. Inogen, Inc. has a 1 year low of $6.14 and a 1 year high of $13.33.
Analysts Set New Price Targets
A number of research firms have recently commented on INGN. Needham & Company LLC reissued a "hold" rating on shares of Inogen in a research note on Wednesday, February 26th. StockNews.com cut Inogen from a "buy" rating to a "hold" rating in a report on Wednesday, February 26th.
View Our Latest Analysis on INGN
Inogen Profile
(
Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Featured Articles
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
